Xenografts using endogenously TM4SF5-expressing hepatoma PLC/PRF/5 cells resulted in significantly less tumor volumes upon treatment of TcxC peptides, compared with those upon control TCsr peptide treatment (Fig. 7C-D). The gene discussed is TM4SF5; the disease is hepatocellular carcinoma.